We serve Chemical Name:(1-(tert-Butoxycarbonyl)-6-(methoxycarbonyl)-1H-indol-2-yl)boronic acid CAS:848357-46-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(1-(tert-Butoxycarbonyl)-6-(methoxycarbonyl)-1H-indol-2-yl)boronic acid
CAS.NO:848357-46-0
Synonyms:[6-methoxycarbonyl-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid
Molecular Formula:C15H18BNO6
Molecular Weight:319.11800
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:501.6ºC at 760 mmHg
Density:1.24g/cm3
Index of Refraction:1.546
PSA:97.99000
Exact Mass:319.12300
LogP:0.89090
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like [6-methoxycarbonyl-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[6-methoxycarbonyl-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[6-methoxycarbonyl-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid Use and application,[6-methoxycarbonyl-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid technical grade,usp/ep/jp grade.
Related News: Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress. (1-(tert-Butoxycarbonyl)-6-(methoxycarbonyl)-1H-indol-2-yl)boronic acid manufacturer Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress. (1-(tert-Butoxycarbonyl)-6-(methoxycarbonyl)-1H-indol-2-yl)boronic acid supplier Of the nearly 4,000 Black women and more than 25,000 white women included in the study, there was no statistically significant difference in breast cancer-related genetic mutations. They were found in 5.65% of Black women and nearly 5.1% of white women. (1-(tert-Butoxycarbonyl)-6-(methoxycarbonyl)-1H-indol-2-yl)boronic acid vendor Of the nearly 4,000 Black women and more than 25,000 white women included in the study, there was no statistically significant difference in breast cancer-related genetic mutations. They were found in 5.65% of Black women and nearly 5.1% of white women. (1-(tert-Butoxycarbonyl)-6-(methoxycarbonyl)-1H-indol-2-yl)boronic acid factory The company has now selected a single engineered iPSC clone, and generated and fully-characterized the master engineered iPSC bank for GMP production of FT819.
